drugset / Trial / NCT03901235

MSC Intratissular Injection in Crohn Disease Patients

NCT03901235

NaSingle-groupOpen-labelTreatment

Summary

The main objective is to assess the efficacy of local injection of MSC on the healing of refractory intestinal and perianal lesions in crohn disease. The second co-primary endpoint is safety.

Timeline

Start
2018-01-15
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy Other

Indications

No indication recorded.